Head-to-Head: can a cheaper drug match a biologic for artery disease?
NCT ID NCT03892785
First seen Nov 26, 2025 · Last updated Jun 11, 2026 · Updated 22 times
Summary
This study compares two treatments—methotrexate (a common, low-cost drug) and tocilizumab (a newer, expensive biologic)—for giant cell arteritis, a blood vessel disease that can cause headaches, vision loss, and stroke. The goal is to see if methotrexate works as well as tocilizumab at preventing relapses while reducing the need for long-term steroids. About 230 adults aged 50 and older with active giant cell arteritis are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Dijon
Dijon, 21079, France
Conditions
Explore the condition pages connected to this study.